MENU

Clinical Trials

A clinical trial is a research study that allows volunteers to receive treatment with a drug or device currently under research testing by a pharmaceutical or biotechnology company. These companies carefully select qualified physicians who serve as "investigators” to lead the study trials.

Arkansas Children's offers opportunities to the community to participate in many studies. Use the search fields below to review the current available studies.

If you have questions about volunteering for research studies, please visit our Frequently Asked Questions page. 

If would like to be contacted about clinical research opportunities, consider joining our Research Registry or sign up to receive text updates on your mobile device.  CLICK HERE to learn more. 

See our currently enrolling studies list.

Title:  
An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Description:  

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL). 

Study Eligibility:  
Ages Eligible for Study: 5 Years to 17 Years (Child)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No


Inclusion Criteria:

Each participant must meet all the following inclusion criteria to be enrolled in the study:
1. Histologically confirmed CD30+ classical HL.
2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).
3. Treatment-naive HL.
4. Have performance scores of greater than or equal to (>=) 50 for Lansky Playperformance or Karnofsky Performance Status.


Exclusion Criteria:
1. Nodular lymphocyte predominant HL.
2. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.
3. Any sensory or motor peripheral neuropathy.
4. Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.
Content Study Link:  
Principal Investigator:  
Category:  
Oncology/Cancer
Contact Information:  
For more information about this study, contact Catherine Redinger at 501-364-4290/RedingerCatherineL@uams.edu or Suzy Hall at 501-364- 4181/Hallsf@archildrens.org
Inclusion/Notes: